Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test™ to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test™ to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.
Learn More

Introducing the Syn-One Test™ from CND Life Sciences

Offering physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy.

seal icon

CLIA-Certified Pathology Lab

test tube icon

Dedication to Science & Research

DNA icon

Patient-Focused Mission

microscope icon

Quality & Reliability at Our Core

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
January 19, 2021

We Can Perform Early Screening for Neurodegenerative Disorders. Does That Mean We Should?

In the November 2020 issue of Movement Disorders, Dommershuijsen and his fellow researchers in the…
Insights
December 2, 2020

Acting Out Your Dreams May Be Dangerous And Could Be an Early Sign of a Neurological Disorder

It is 4:30 AM and you are sound asleep. Suddenly your significant other screams and…
Insights
November 10, 2020

Detecting Alpha-Synuclein in Parkinson’s and Other Synucleinopathies: Proper Pathological Methods Matter

The identification of a reliable biomarker in neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s...
VIEW ALL INSIGHTS

Check out press releases, news alerts and coverage of CND happenings.

News Release
January 7, 2021

CND Life Sciences to Present at Biotech Showcase Investor Conference

Poised for Growth After Successfully Launching First Skin-Based Test for Parkinson's
In the News
January 4, 2021

German Biotech Initiates Phase 1b Clinical Trial of Synucleinopathy Treatment

MODAG, a German biotechnology company, announced that it would begin an in-patient clinical trial of anle138b,…
In the News
December 22, 2020

Dr. Todd Levine Talks With Medical World News About the Potential of the Syn-One Test™ to Impact Patients’ Care

Todd Levine, MD, Co-Founder and Chief Medical Officer of CND Life Sciences was recently interviewed…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Syn-One Test™ Kit

The Syn-One Test provides objective pathological evidence to aid in the diagnosis of a synucleinopathy. Simply collect three small punch skin biopsies from your patient, send them to our CLIA-certified lab, and CND Life Sciences will provide important visual insights to support a diagnosis. If you are a clinician, click below to order a Syn-One Test Biopsy Kit.

Order a Kit